Expansion Partnerships Horizon has built a robust partner ecosystem with Promega (Mar 2022) and YCharOS (Jul 2021), plus ongoing product launches such as single guide RNA and Cas9 cell lines, signaling opportunities to pursue joint selling, bundled offerings, and accelerated market access through Revvity’s global network.

CRISPR Tooling Core business centers on gene editing and modulation tools, including predesigned sgRNA offerings and stable Cas9 cell lines for knockouts and dCas9 activation, creating opportunities to upsell additional sgRNA libraries, CRISPR reagents, and reference standards to academic labs and CROs.

Diagnostics Focus Horizon’s emphasis on diagnostic workflows and RNA fusion reference standards for FFPE samples positions it to sell validation materials, controls, and standardized assay components to academic medical centers, clinical laboratories, and translational research teams.

Revvity Channel As part of the Revvity family with a Cambridge headquarters and US/Japan offices, Horizon can leverage Revvity’s sales channels and installed base to accelerate cross-market adoption among pharma, biotech, and academic customers seeking integrated gene editing and diagnostic solutions.

Market Validation Industry recognition such as awards and strategic partnerships bolster credibility for premium offerings, supporting sales pitches to procurement teams and enabling expansion into larger enterprise accounts and translational research programs.